- Home
- OCUL vs ICUI Comparison
OCUL vs ICUI Comparison
Compare OCUL & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OCUL | ICUI |
|---|---|---|
| Founded | 2006 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.2B |
| IPO Year | 2014 | 1992 |
Fundamental Metrics
Financial Performance| Metric | OCUL | ICUI |
|---|---|---|
| Price | $14.30 | $148.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 6 |
| Target Price | $22.56 | ★ $183.60 |
| AVG Volume (30 Days) | ★ 3.8M | 236.9K |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $55,783,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14.88 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.79 | $107.00 |
| 52 Week High | $16.44 | $175.51 |
Technical Indicators
Market Signals| Indicator | OCUL | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 60.83 | 63.67 |
| Support Level | $11.15 | $141.10 |
| Resistance Level | $16.44 | $148.95 |
| Average True Range (ATR) | 0.77 | 3.94 |
| MACD | 0.24 | -0.34 |
| Stochastic Oscillator | 59.49 | 60.85 |
Price Performance
Historical ComparisonAbout OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.